News in other languages: HANDOK Inc.

27/07/23

Hogere omzet en kleiner verlies voor Argenx

Managers and Directors: HANDOK Inc.

Manager	Title	Age	Since
Jin-Ki Baik CEO	Chief Executive Officer	69	-
Young-Jin Kim CEO	Chief Executive Officer	70	01/01/1996
Hyeon-Cheol Lee DFI	Director of Finance/CFO	58	-

Director	Title	Age	Since
Young-Jin Kim CHM	Chairman	70	01/01/1996
Jin-Ki Baik BRD	Director/Board Member	69	-
Young Kim BRD	Director/Board Member	58	-

More insiders

Handok Inc is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment mainly manufactures and sells prescription and over-the-counter drugs, including treatments for diabetes, hypertension, kidney diseases, respiratory diseases, central nervous system disorders, rare diseases, as well as anticancer drugs. The Medical Device segment mainly sells medical devices and diagnostic reagents. The Contract Manufacturing segment mainly provides contract manufacturing and quality control services for pharmaceuticals. The Real Estate Leasing segment mainly engages in the real estate leasing business.

Employees

910

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	KRW 8,280.00	+0.73%	6,226
05/11/26	KRW 8,220.00	+1.99%	5,910
04/11/26	KRW 8,060.00	-0.98%	974
03/11/26	KRW 8,140.00	-0.49%	6,876
02/11/26	KRW 8,180.00	-0.37%	4,074

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 06/11/2026			5-day change	1st Jan Change
8,280.00 ^KRW	+0.73%		-1.19%	-26.07%

30/04	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
11/02	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI

Market Cap	108B 78.88M 70.75M 64.66M 59.02M 111M 7.41B 115M 779M 311M 3.96B 296M 290M 12.49B	P/E 2024	-3.16x	P/E 2025	-69x
Enterprise Value	458B 336M 301M 275M 251M 474M 31.58B 488M 3.32B 1.32B 16.85B 1.26B 1.23B 53.19B	EV / Sales 2024	0.95x	EV / Sales 2025	0.93x
Free-Float	52.16%	Yield 2024	1.66%	Yield 2025	1.79%

30/04	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
11/02	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI
10/02	Handok Q4 operating profit 4.2 billion won, swings to profit from year earlier	RE
30/10/25	Handok Q3 operating profit 287 million won, swings to profit from year earlier	RE
11/09/25	Teva Handok Announces UZEDY Receives Regulatory Approval from the South Korean Ministry of Food and Drug Safety	CI
12/05/25	Handok To Divest 9 Billion Won Worth Of Own Shares	RE
30/04/25	Handok Q1 Operating Loss 1.6 Billion Won	RE
05/02/25	Handok Q4 Operating Loss 2.7 Billion Won	RE
09/12/24	HANDOK Inc. announced that it expects to receive KRW 30 billion in funding	CI
26/06/24	WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	CI
24/05/24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT
24/05/24	Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	CI
16/04/24	Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	MT

14/02/24	Sobi and Handok establish joint venture for rare disease business in South Korea	AQ
03/04/17	Handok : Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017	BU

HANDOK Inc. Stock

Stocks

A002390

KR7002390003

Pharmaceuticals

Valuation: HANDOK Inc.

Chart: HANDOK Inc.

Latest news: HANDOK Inc.

Press Releases: HANDOK Inc.

News in other languages: HANDOK Inc.

Quotes and Performance

Price Extremes

Managers and Directors: HANDOK Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+0.73%
1 week	-1.19%
Current month	+0.85%
1 month	-3.27%
3 months	-10.97%
6 months	-18.50%
Current year	-26.07%

1 week	7,810	8,550
1 month	7,810	9,360
Current year	6,460	11,820
1 year	6,460	12,150
3 years	6,460	20,300
5 years	6,460	24,100
10 years	6,460	44,750

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HANDOK INC.	+0.73%	-1.19%	-25.61%	-31.63%	78.95M
ELI LILLY AND COMPANY	+0.12%	-3.72%	+45.59%	+129.31%	1,216B
JOHNSON & JOHNSON	+0.49%	-0.01%	+46.11%	+80.08%	656B
ABBVIE INC.	+0.47%	-1.84%	+32.15%	+105.00%	509B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	384B
MERCK & CO., INC.	-0.07%	-1.87%	+71.05%	+40.62%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	311B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	293B
AMGEN INC.	+0.10%	-1.20%	+45.89%	+68.76%	249B
GILEAD SCIENCES, INC.	+0.27%	-1.66%	+36.02%	+106.86%	208B
Average	-0.09%	+0.66%	+33.75%	+65.71%	418.79B
Weighted average by Cap.	-0.06%	+0.03%	+42.22%	+88.46%

	2024	2025
Net sales	507B 372M 334M 305M 278M 525M 34.97B 541M 3.68B 1.47B 18.66B 1.4B 1.37B 58.91B	535B 392M 352M 322M 294M 553M 36.89B 571M 3.88B 1.55B 19.68B 1.47B 1.44B 62.14B
Net income	-52.56B -38.55M -34.57M -31.6M -28.84M -54.34M -3.62B -56.05M -381M -152M -1.93B -145M -142M -6.1B	-2.15B -1.58M -1.42M -1.29M -1.18M -2.23M -148M -2.3M -15.6M -6.22M -79.19M -5.93M -5.8M -250M
Net Debt	317B 233M 209M 191M 174M 328M 21.88B 338M 2.3B 917M 11.67B 874M 855M 36.85B	351B 257M 231M 211M 192M 362M 24.16B 374M 2.54B 1.01B 12.89B 965M 944M 40.7B